Alpine Immune Sciences Inc ALPN:NASDAQ

Last Price$8.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.07(0.83%)
Bid (Size)$7.80 (1)
Ask (Size)$9.20 (4)
Day Low / High$8.30 - 9.11
Volume147.3 K
  • Latest Stories
  • Commentary and Analysis
Horizon Therapeutics Working With Alpine Immune Sciences to Develop Therapies for Autoimmune, Inflammatory Diseases
9:02AM ET 12/16/2021 MT Newswires

Horizon Therapeutics (HZNP) and Alpine Immune Sciences (ALPN) on Thursday entered into an exclusive agreement to develop novel protein-based therapies for...

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Reports Q3 Revenue $8.5M
4:13PM ET 11/10/2021 MT Newswires

...

Insider Buy: Alpine Immune Sciences
9:26AM ET 9/22/2021 MT Newswires

Peter A. Thompson, 10% Owner, Director, on September 17, 2021, executed a purchase for 1,010,637 shares in Alpine Immune Sciences (ALPN) for $9,499,988....

Insider Sell: Alpine Immune Sciences
5:24PM ET 9/21/2021 MT Newswires

Jay Venkatesan, 10% Owner, Director, on September 17, 2021, sold 400,000 shares in Alpine Immune Sciences (ALPN) for $3,760,000. Following the Form 4...

Insider Buy: Alpine Immune Sciences
5:24PM ET 9/21/2021 MT Newswires

Xiangmin Cui, 10% Owner, Director, on September 17, 2021, executed a purchase for 1,542,553 shares in Alpine Immune Sciences (ALPN) for $14,499,998....

Insider Sell: Alpine Immune Sciences
5:23PM ET 9/21/2021 MT Newswires

Mitchell Gold, 10% Owner, Director, Executive Chairman and CEO, on September 17, 2021, sold 445,262 shares in Alpine Immune Sciences (ALPN) for $4,212,964....

Alpine Immune Sciences Announced $91 Million Securities Purchase Deal; Shares Climb
11:48AM ET 9/15/2021 MT Newswires

Alpine Immune Sciences (ALPN) announced Wednesday a $91 million definitive securities purchase agreement for the sale of common shares and prefunded...

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q2 Revenue $7.2M, vs. Street Est of $7.77M
4:09PM ET 8/10/2021 MT Newswires

...

Alpine Immune Sciences Signs Deal With Merck to Evaluate ALPN-202/Keytruda Combination
10:00AM ET 6/30/2021 MT Newswires

Alpine Immune Sciences (ALPN) has signed a clinical trial collaboration and supply deal with Merck (MRK) to evaluate the safety and efficacy of Alpine's...

Alpine Immune Doses First Patient in Mid-Stage Study of Lupus Drug Candidate; Receives $45 Million Milestone Payment
8:55AM ET 6/24/2021 MT Newswires

Alpine Immune Sciences (ALPN) said Thursday it has dosed the first patient in a phase 2 study of ALPN-101 in patients with systemic lupus erythematosus, an...